The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Vivus Inc.

  • VVUS
  • NASDAQ
  • Consumer Products
  • Latest 4.79
  • Currency US$
  • Change -0.13
  • Percent Change -2.642 %
  • Volume 1,667,559
  • Thu Jul 10, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 4.84
  • Previous Close 4.92
  • High 4.89
  • Low 4.77
  • Bidx2 4.79
  • Askx7 4.87
  • 52-week High07/12 15.40
  • 52-week Low05/22 4.56
  • Beta 1.494
  • Market Cap 494.81M
  • EPS -1.06
  • P/E
  • Forward P/E
  • PEG
  • Annual Dividend 0.0000
  • Yield
Globe Investor - GIT Upsells
It's never been a better time to get Globe Unlimited
Try Globe Unlimited, featuring new Globe Investor Tools,
for a special trial rate. Only 99¢ for your first month.


Are you a Globe Investor Gold subscriber?
You qualify for complimentary access to Globe Unlimited.
Visit: globeandmail.com/globeplusunlimited
Try it today

News

Financials & Calendars

Income Statement

  • Sales $113,660,000
  • Earnings $-136,420,000
  • Return on Equity n/a

Cash Flow

  • Cash Flow --
  • Cash $89,650,000
  • Current Ratio 8.28

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $420,890,000
  • Liabilities $279,420,000
  • Liabilities-to-Equity Ratio 1.98

Price Ratios

  • Price to Sales 4.35
  • Price to Book 3.50
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings May 5 $-0.34 Aug 5 $-0.39
Surprises May 5 -55.88% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Jul 10, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa(TM), is expected to complete Phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in Phase 3 development with avanafil, its PDE5 inhibitor drug candidate, and in Phase 2 development of Luramist(TM), its drug candidate for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS.

Related Securities
Symbol Type Latest % Chg

Officers

  • Michael J. Astrue Non-executive Chairman of the
  • Seth H. Z. Fischer Chief Executive Officer
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

1172 CASTRO ST STE 200
MOUNTAIN VIEW, CA
94040

Phone: (650)-934-5265
Fax: (650)-9345389

ir@vivus.com
www.vivus.com

Ideas & Discussion

Live Discussion of VVUS on StockTwits